Barclays
VKTX icon

Barclays’s Viking Therapeutics VKTX Stock Holding History

Barclays’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,400
Closed -$1.29M – 5494
2024
Q3 		$1.29M Buy
+20,400
New +$1.2M ﹤0.01% 3181
2018
Q4 		– Sell
-253,200
Closed -$4.41M – 7364
2018
Q3 		$4.41M Buy
+253,200
New +$3.01M ﹤0.01% 1939

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Barclays's VKTX Position: Q2 2026 in Review

Barclays reduced its Viking Therapeutics (VKTX) stake by 25% in Q2 2026, selling an estimated $558K and leaving 52,991 shares worth $2.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2316.

Barclays first reported a position in VKTX in Q4 2017 and has held it in 35 quarters since. The position peaked at $18.2M in Q4 2025. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Barclays held 52,991 shares of Viking Therapeutics worth $2.07M as of Q2 2026.
  • Barclays sold 17,288 Viking Therapeutics shares in Q2 2026, an estimated $558K.
  • Viking Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2316 holding.
  • Barclays first reported a position in Viking Therapeutics in Q4 2017 and has held it in 35 quarters since.
  • Barclays's Viking Therapeutics position peaked at $18.2M in Q4 2025.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.